SIDE EFFECTS OF PROTON PUMP INHIBITORS DURING LONG TERM USE: FOCUS ON THE RESPIRATORY ORGANS
Main Article Content
Abstract
Proton pump inhibitors (PPIs) are the most effective drugs for treating acid-related diseases. In recent decades, the use of PPIs has increased exponentially.
For a long time, PPIs were considered completely safe drugs for both short-term and long-term use. However, modern clinical guidelines note that when prescribing PPIs in large doses for a long period, the possibility of side effects should be taken into account. In recent years, a number of foreign reviews have been published that examine the associations between PPIs and a number of diseases/conditions.
We searched the PubMed and Scopus information databases for publications on the safety of PPI use, including sources up to 12.01.2023. In this review, we examined the effect of long-term use of PPIs on the respiratory system.
Compared with other side effects, changes in the respiratory system have received less attention, but an increased risk of community-acquired pneumonia with long-term use of PPIs has been recognized as likely. Additional prospective studies are needed to elucidate the cause-and-effect mechanisms of the relationship between PPIs and brocho-obstructive diseases.
Keywords
Author Biographies
Дмитрий Иванович Трухан,
Dmitry I. Trukhan
MD, PhD, docent. Professor of the Department of Internal Medicine and Polyclinic Therapy
Сергей Николаевич Филимонов,
doctor of medical sciences, professor, Head of the Department of Human Ecology, Public Health and HealthcareArticle Details
Information about financing and conflict of interests
The authors declare that they have no apparent or potential conflicts of interest related to the publication of this article.
This work is licensed under a Creative Commons Attribution 4.0 License.
How to Cite
References
Trukhan DI. Rational pharmacotherapy in real clinical practice through the prism of multimorbidity and drug safety. Clinical review for general practice. 2020; 2: 29–39. Russian (Трухан Д.И. Рациональная фармакотерапия в реальной клинической практике сквозь призму мультиморбидности и лекарственной безопасности //Клинический разбор в общей медицине. 2020. № 2. С. 29-39.) DOI: 10.47407/kr2020.1.2.00015
Trukhan DI, Konshu NV. Rational pharmacotherapy in internal diseases clinic through the prism of multimorbidity and drug safety. Handbook for Practitioners Doctors. 2019; 2: 10-18. Russian (Трухан Д.И., Коншу Н.В. Рациональная фармакотерапия в клинике внутренних болезней сквозь призму мультиморбидности и лекарственной безопасности //Справочник поликлинического врача. 2019. № 2. С. 10-18)
Lazebnik LB, Tkachenko EI, Abdulganiyeva DI, Abdulkhakov RA, Abdulkhakov SR, Avaluyeva EB, et al. VI National guidelines for the diagnosis and treatment of acid-related and Helicobacter pylori-associated diseases (VI Moscow agreement). Experimental and Clinical Gastroenterology. 2017; (2): 3-21. Russian (Лазебник Л.Б., Ткаченко Е.И., Абдулганиева Д.И., Абдулхаков Р.А., Абдулхаков С.Р., Авалуева Е.Б., и др. VI Национальные рекомендации по диагностике и лечению кислотозависимых и ассоциированных с Helicobacter pylori заболеваний (VI Московские соглашения) //Экспериментальная и клиническая гастроэнтерология. 2017. № 2. С. 3-21)
Al-Aly Z, Maddukuri G, Xie Y. Proton pump inhibitors and the kidney: implications of current evidence for clinical practice and when and how to deprescribe. Am J Kidney Dis. 2020; 75: 497-507. DOI: 10.1053/j.ajkd.2019.07.012
Novotny M, Klimova B, Valis M. PPI Long Term Use: Risk of Neurological Adverse Events? Front Neurol. 2019; 9: 1142. DOI: 10.3389/fneur.2018.01142
Singh A, Cresci GA, Kirby DF. Proton Pump Inhibitors: Risks and Rewards and Emerging Consequences to the Gut Microbiome. Nutr Clin Pract. 2018; 33(5): 614-624. DOI: 10.1002/ncp.10181
Naito Y, Kashiwagi K, Takagi T, Andoh A, Inoue R. Intestinal Dysbiosis Secondary to Proton-Pump Inhibitor Use. Digestion. 2018; 97(2): 195-204. DOI: 10.1159/000481813
Fohl AL, Regal RE. Proton pump inhibitor-associated pneumonia: not a breath of fresh air after all? World J Gastrointest Pharmacol Ther. 2011; 2: 17-26. DOI: 10.4292/wjgpt.v2.i3.17
Wang CH, Li CH, Hsieh R, Fan CY, Hsu TC, Chang WC, et al. Proton pump inhibitors therapy and the risk of pneumonia: a systematic review and meta-analysis of randomized controlled trials and observational studies. Expert Opin Drug Saf. 2019; 18: 163-172. DOI: 10.1080/14740338.2019.1577820
Nguyen PA, Islam M, Galvin CJ, Chang CC, An SY, Yang HC, et al. Meta-analysis of proton pump inhibitors induced risk of community-acquired pneumonia. Int J Qual Health Care. 2020; 32: 292-299. DOI: 10.1093/intqhc/mzaa041
Giuliano C, Wilhelm SM, Kale-Pradhan PB. Are proton pump inhibitors associated with the development of community-acquired pneumonia? A meta-analysis. Expert Rev Clin Pharmacol. 2012; 5(3): 337-344. DOI: 10.1586/ecp.12.20
Xun X, Yin Q, Fu Y, He X, Dong Z. Proton pump inhibitors and the risk of community-acquired pneumonia: an updated meta-analysis. Ann Pharmacother. 2022; 56: 524-532. DOI: 10.1177/10600280211039240
Lambert AA, Lam JO, Paik JJ, Ugarte-Gil C, Drummond MB, Crowell TA. Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis. PLoS One. 2015; 10(6): e0128004. DOI: 10.1371/journal.pone.0128004
Othman F, Crooks CJ, Card TR. Community acquired pneumonia incidence before and after proton pump inhibitor prescription: population based study. BMJ. 2016; 355: i5813. DOI: 10.1136/bmj.i5813
Zirk-Sadowski J, Masoli JA, Delgado J, Hamilton W, Strain WD, Henley W, et.al. Proton-Pump Inhibitors and Long-Term Risk of Community-Acquired Pneumonia in Older Adults. J Am Geriatr Soc. 2018; 66(7): 1332-1338. DOI: 10.1111/jgs.15385
Ble A, Zirk-Sadowski J, Masoli JA. Reply to: Proton Pump Inhibitors and Long-term Risk of Community-acquired Pneumonia in Older Adults. J Am Geriatr Soc. 2018; 66(12): 2428-2429. DOI: 10.1111/jgs.15637
Maret-Ouda J, Panula J, Santoni G, Xie S, Lagergren J. Proton pump inhibitor use and risk of pneumonia: a self-controlled case series study. J Gastroenterol. 2023; 58(8): 734-740. DOI: 10.1007/s00535-023-02007-5
Charpiat B, Bleyzac N, Tod M. Proton Pump Inhibitors are Risk Factors for Viral Infections: Even for COVID-19? Clin Drug Investig. 2020; 40(10): 897-899. DOI: 10.1007/s40261-020-00963-x
Fatima K, Almas T, Lakhani S, Jahangir A, Ahmed A, Siddiqui A, et al. The use of proton pump inhibitors and COVID-19: a systematic review and meta-analysis. Trop Med Infect Dis. 2022; 7: 37. DOI: 10.3390/tropicalmed7030037
Almario CV, Chey WD, Spiegel BMR. Increased Risk of COVID-19 Among Users of Proton Pump Inhibitors. Am J Gastroenterol. 2020; 115(10): 1707-1715. DOI: 10.14309/ajg.0000000000000798
Li GF, An XX, Yu Y, Jiao LR, Canarutto D, Yu G, et al. Do proton pump inhibitors influence SARS-CoV-2 related outcomes? A meta-analysis. Gut. 2021; 70: 1806-1808. DOI: 10.1136/gutjnl-2020-323366
Israelsen SB, Ernst MT, Lundh A, Lundbo LF, Sandholdt H, Hallas J, Benfield T. Proton Pump Inhibitor Use Is Not Strongly Associated With SARS-CoV-2 Related Outcomes: A Nationwide Study and Meta-analysis. Clin Gastroenterol Hepatol. 2021; 19(9): 1845-1854.e6. DOI: 10.1016/j.cgh.2021.05.011
Toubasi AA, AbuAnzeh RB, Khraisat BR, Al-Sayegh TN, AlRyalat SA. Proton Pump Inhibitors: Current Use and the Risk of Coronavirus Infectious Disease 2019 Development and its Related Mortality. Meta-analysis. Arch Med Res. 2021; 52(6): 656-659. DOI: 10.1016/j.arcmed.2021.03.004
Yan C, Chen Y, Sun C, Ahmed MA, Bhan C, Guo Z, et al. Does Proton Pump Inhibitor Use Lead to a Higher Risk of Coronavirus Disease 2019 Infection and Progression to Severe Disease? a Meta-analysis. Jpn J Infect Dis. 2022; 75(1): 10-15. DOI: 10.7883/yoken.JJID.2021.074
Pranata R, Huang I, Lawrensia S, Henrina J, Lim MA, Lukito AA, et al. Proton pump inhibitor on susceptibility to COVID-19 and its severity: a systematic review and meta-analysis. Pharmacol Rep. 2021; 73(6): 1642-1649. DOI: 10.1007/s43440-021-00263-x
Kamal F, Khan MA, Sharma S, Imam Z, Howden CW. Lack of Consistent Associations Between Pharmacologic Gastric Acid Suppression and Adverse Outcomes in Patients With Coronavirus Disease 2019: Meta-Analysis of Observational Studies. Gastroenterology. 2021; 160(7): 2588-2590.e7. DOI: 10.1053/j.gastro.2021.02.028
Ramachandran P, Perisetti A, Gajendran M, Jean-Louis F, Bansal P, Dwivedi AK, Goyal H. Pre-hospitalization proton pump inhibitor use and clinical outcomes in COVID-19. Eur J Gastroenterol Hepatol. 2022; 34(2): 137-141. DOI: 10.1097/MEG.0000000000002013
Kim HB, Kim JH, Wolf BJ. Acid suppressant use in association with incidence and severe outcomes of COVID-19: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2022; 78(3): 383-391. DOI: 10.1007/s00228-021-03255-1
Wang WT, Li CY, Chang YT, Bai YM, Tsai SJ, Chen TJ, et al. Proton-pump inhibitors are associated with an increased risk of asthma: A nationwide nested case-control study. Allergy Asthma Proc. 2023; 44(5): 345-353. DOI: 10.2500/aap.2023.44.230035
Wang YH, Wintzell V, Ludvigsson JF, Svanström H, Pasternak B. Association Between Proton Pump Inhibitor Use and Risk of Asthma in Children. JAMA Pediatr. 2021; 175(4): 394-403. DOI: 10.1001/jamapediatrics.2020.5710
Janetzki JL, Sykes MJ, Ward MB, Pratt NL. Proton pump inhibitors may contribute to progression or development of chronic obstructive pulmonary disease-A sequence symmetry analysis approach. J Clin Pharm Ther. 2021; 46(6): 1687-1694. DOI: 10.1111/jcpt.13520
Haastrup PF, Jarbøl DE, Thompson W, Hansen JM, Søndergaard J, Rasmussen S. When does proton pump inhibitor treatment become long term? A scoping review. BMJ Open Gastroenterol. 2021; 8: e000563 DOI: 10.1136/bmjgast-2020-000563
Tawam D, Baladi M, Jungsuwadee P, Earl G, Han J. The Positive Association between Proton Pump Inhibitors and Clostridium Difficile Infection. Innov Pharm. 2021; 12(1): 10.24926/iip.v12i1.3439. DOI: 10.24926/iip.v12i1.3439
Lespessailles E, Toumi H. Proton Pump Inhibitors and Bone Health: An Update Narrative Review. Int J Mol Sci. 2022; 23(18): 10733. DOI: 10.3390/ijms231810733
Makunts T, Cohen IV, Awdishu L, Abagyan R. Analysis of postmarketing safety data for proton-pump inhibitors reveals increased propensity for renal injury, electrolyte abnormalities, and nephrolithiasis. Sci Rep. 2019; 9: 2282. DOI: 10.1038/s41598-019-39335-7
Park CH, Kim EH, Roh YH, Kim HY, Lee SK. The association between the use of proton pump inhibitors and the risk of hypomagnesemia: a systematic review and meta-analysis. PLoS One. 2014; 9: e112558. DOI: 10.1371/journal.pone.0112558
Zhang ML, Fan YX, Meng R, Cai WK, Yin SJ, Zhou T, et al. Proton pump inhibitors and cancer risk: an umbrella review and meta-analysis of observational studies. Am J Clin Oncol. 2022; 45: 475-485. DOI: 10.1097/COC.0000000000000949
Sehested TSG, Gerds TA, Fosbøl EL, Hansen PW, Charlot MG, Carlson N, et al. Long-term use of proton pump inhibitors, dose-response relationship and associated risk of ischemic stroke and myocardial infarction. J Intern Med. 2018; 283: 268-281. DOI: 10.1111/joim.12698
Guo YR, Liu XM, Wang GX. Exposure to proton pump inhibitors and risk of diabetes: A systematic review and meta-analysis. World J Diabetes. 2023; 14(2): 120-129. DOI: 10.4239/wjd.v14.i2.120
Maideen NMP. Adverse Effects Associated with Long-Term Use of Proton Pump Inhibitors. Chonnam Med J. 2023; 59(2): 115-127. DOI: 10.4068/cmj.2023.59.2.115
Targownik LE, Fisher DA, Saini SD. AGA clinical practice update on de-prescribing of proton pump inhibitors: expert review. Gastroenterology. 2022; 162: 1334-1342. DOI: 10.1053/j.gastro.2021.12.247